Investors Urged to Take Action Against Regencell Bioscience by June 2026 Deadline

Important Reminder for Regencell Bioscience Investors

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, is currently reaching out to investors of Regencell Bioscience Holdings Limited (NASDAQ: RGC). The firm is looking into claims against the company, particularly due to serious allegations regarding misleading statements and market manipulation that may have affected shareholder value significantly.

As investors who acquired Regencell shares between October 28, 2024, and October 31, 2025, it is crucial to remain informed about the upcoming deadline for filing a motion to serve as lead plaintiff in a federal securities class action, which is set for June 23, 2026. This opportunity lets investors unite and seek compensation for potential losses incurred as a result of the company's actions.

Allegations Against Regencell

The class action lawsuit claims that Regencell and its executives violated federal securities laws by not disclosing critical information about their market conditions. Specifically, the allegations state that Regencell was exposed to manipulation in the stock market, leading to extreme financial risk for investors. Additionally, the company reportedly failed to inform shareholders about its vulnerability to regulatory scrutiny, which could result in significant penalties and reputational damage.

The tipping point occurred on October 31, 2025, when Regencell publicly stated that it had received a subpoena from the U.S. Department of Justice (DOJ) concerning its trading practices. Following this disclosure, the company's stock saw a dramatic decline, plummeting by 18.56%, a clear reflection of investor panic and loss of trust.

Role of the Lead Plaintiff

The role of the lead plaintiff is pivotal in such a class action lawsuit, as this individual represents the interests of all involved shareholders. A lead plaintiff typically has the most significant financial stake in the lawsuit while also being representative of other investors within the class. It's vital that any investor wishing to take on this role does so through proper legal channels and has adequate support from trained legal professionals.

If you believe you may have a valid claim or if you need any further assistance, Faruqi & Faruqi encourages you to reach out. The firm has vast experience in collecting hundreds of millions of dollars for investors since its inception, making it a formidable player in securities litigation.

Investors are encouraged to get in touch with Josh Wilson, a senior partner at the firm, at 877-247-4292 or 212-983-9330 (Ext. 1310) to evaluate their options. Furthermore, those with any information related to Regencell's actions—such as whistleblowers, former employees, or fellow investors—are likewise urged to come forward.

In the dynamic landscape of securities litigation, being proactive is essential. Keeping track of developments, understanding your rights, and acting swiftly could make a significant difference in receiving the restitution that deserves after substantial losses.

For more comprehensive information regarding the Regencell class action and to stay updated on ongoing proceedings, visit Faruqi & Faruqi.

Conclusion

The Securities and Exchange Commission (SEC) and other regulatory bodies are increasingly scrutinizing companies for transparency and compliance. Investors of Regencell Bioscience must be vigilant and informed as they navigate these turbulent waters. Addressing these concerns now will position them better for potential recovery in the future. Don’t hesitate; time is of the essence, and June 23, 2026, is just around the corner.